The outbreak of the Wuhan coronavirus, which was recently labeled a pandemic by the World Health Organization (WHO), has highlighted the longstanding issue of America’s dependence on China for medical supplies.
President Donald Trump is expected to announce a new executive order aimed at ensuring medical supplies and pharmaceuticals are made in America, in response to the spread of the virus.
The United States is “dramatically dependent” on China for medical supplies that include among them masks, scans, prescription drugs, and their ingredients, according to Rosemary Gibson, a senior adviser at the Hastings Center, a bioethics research institute, and the co-author of “China RX: Exposing the Risks of America’s Dependence on China for Medicine.”
“Our dependence is a risk to our national security,” she told The Epoch Times. “For prescription drugs, 90 percent of the core ingredients, the chemicals, and other ingredients depend on China.”
Gibson said the dependence on China is a huge risk because it exposes the lack of availability of certain medicines that are crucially needed in the United States, especially antibiotics. Doctors and nurses could also be at risk if there’s a shortage of masks and protective gowns.
“This is about life and death here,” Gibson added. “This is about survivability.”
Rubio praised the administration’s expected executive order, a day before chairing a March 12 hearing titled, “The Coronavirus and America’s Small Business Supply Chain.” He serves as chairman of the Senate’s Committee on Small Business and Entrepreneurship.
“The Trump Administration’s forthcoming Executive Order is a very strong first step toward increasing domestic production by enforcing Buy American requirements for pharmaceuticals and medical supplies, as well as fast-tracking FDA approval of critical products impacted by the coronavirus outbreak’s strain on the supply chain.”
Gibson said the reliance on China for medical supplies stems from the communist regime’s engagement in a “strategy of illegal trade practices to fix prices to dump products [and] medicines on the global market at below-market prices.”
“They subsidized their domestic companies, they don’t want to import our products and so that has driven out western companies,” she said. “It’s not just lower costs, it’s market manipulation.”
Robert J. Bunker, adjunct research professor at the U.S. Army War College’s Strategic Studies Institute, told The Epoch Times it would be a “massive strategic mistake for the United States to allow itself to continue to be vulnerable to Chinese ‘pharmaceutical blackmail’ potentials.”
“The communist regime could use such leverage for international gains such as further cracking down on Hong Kong or isolating Taiwan by threatening to withhold pharmaceutical deliveries to the United States if its demands are not met,” he said via email.